A Double Blind Placebo Controlled Trial of Daunomycin and Cytosine Arabinoside With or Without rhG-CSF in Elderly Patients With Acute Myeloid Leukemia

Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients

E Pogosova-Agadjanyan;X Hua;M Othus;F Appelbaum;T Chauncey;H Erba;M Fitzgibbon;J Godwin;I Jenkins;M Fang;A Moseley;J Naru;J Radich;B Willborg;C Willman;F Wu;S Meshichi;D Stirewalt Biomarker Research Mar 16;11(1):31. doi: 10.1186/s40364-023-00461-0

PMid: PMID36927800 | PMC number: PMC10022072

Improved outcomes with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: Analysis of SWOG trial data

M Othus;G Garcia-Manero;J Godwin;J Weick;F Appelbaum;H Erba;E Estey Haematologica Jan 1;108(1):42-47

PMid: PMID35833298 | PMC number: PMC9827148

Long Non-coding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia

J Farrar;J Smith;M Othus;B Huang;Y Wang;R Ries;T Hylkema;E Pogosova-Agadjanyan;A Leonti;T Shaw;T Triche;A Gamis;R Aplenc;E Kolb;X Ma;D Stirewalt;T Alonzo;S Meshinchi Journal of Clinical Oncology Jun 1;41(16):2949-2962

PMid: PMID36795987 | PMC number: PMC10414715

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 AML risk stratifications: A SWOG report

C Termini;A Moseley;M Othus;F Appelbaum;T Chauncey;H Erba;M Fang;S Lee;J Naru;E Pogosova- Agadjanyan;J Radich;C Willman;F Wu;S Meshinchi;D Stirewalt Haematologica. Apr 6. doi: 10.3324/haematol.2023.282733. Online ahead of print

PMid: PMID37021537 | PMC number: PMC Journal - In Process

A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML

J Farrar;J Smith;M Othus;B Huang;Y Wang;R Ries;T Hylkema;E Pogosova-Agadjanyan;A Leonti;T Shaw;T Triche;A Gamis;R Aplenc;E Kolb;X Ma;D Stirewalt;T Alonzo;S Meshinchi ASH Annual Meeting (Dec 10 thru 13, 2022, New Orleans, LA), poster

Associations Between Complete Remission and 2-3 Year Survival Following 7+3 Induction for Acute Myeloid Leukemia

M Othus;G Garcia-Manero;J Godwin;J Weick;D Stirewalt;F Appelbaum;H Erba;E Estey Leukemia & Lymphoma, Aug;62(8):1967-1972; Mar 10;1-6. doi: 10.1080/10428194.2021.1885663. Online ahead of print.2021

PMid: PMID3719833

Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report

J Naru;M Othus;C Lin;A Moseley;A List;C Willman;E Pogosova-Agadjanyan;F Wu;F Appelbaum;H Erba;I-M Chen;I Jenkins;J Kennedy;J Delrow;J Whiteaker;J Radich;J Godwin;L Beppu;M Fitzbiggon;M Fang;P Wang;P Gafken;R Ivey;S Meshinchi;T Chauncey;T Lorentzen;U Voytovich;A Paulovich;D Stirewalt American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #522

Global Proteomic Profiling Identifies Novel Prognostic Biomarkers in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A First-Of-Its-Kind Report Form the Fred Hutch and SWOG

D Stirewalt;M Othus;Y Naru;J Kennedy;E Pogosova-Agadjanyan;F Appelbaum;L Beppu;T Chauncey;J Delrow;H Erba;P Gafken;J Godwin;M Fitzgibbons;X Hua;I Jenkins;M Fang;R Ivey;C Lin;T Lorentzen;A Moseley;J Radich;J Voytovich;P Wang;J Whiteaker;C Willman;F Wu;S Meshinchi;A Paulovich American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #799

Association of immunophenotype with expression of topoisomerase II a and B in adult acute myeloid leukemia

A Michelson;S Mcdonough;C Willman;E Koegle;J Anderson;J Godwin;S Petersdorf;A List;M Othus;F Appelbaum;J Radich;R Ganapathi;A Advani;R Ganapathi Scientific Reports Mar 26;10(1):5486

PMid: PMID32218491 | PMC number: PMC7099013

AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

E Pogosova-Agadjanyan;A Moseley;M Othus;F Appelbaum;T Chauncey;I-M Chen;HP Erba;JE Godwin;I Jenkins;M Fang;M Huyhn;K Kopecky;A List;J Naru;G Pogosov;J Radich;E Stevens;B Willborg;C Willman;BL Wood;Q Zhang;S Meshinchi;D Stirewalt Biomarker Research Aug 12;8:29

PMid: PMID32817791 | PMC number: PMC7425159

Economic evaluations in NCI-sponsored network cancer clinical trials

VT Nghiem;R Vaidya;GH Lyman;DL Hershman;SD Ramsey;JM Unger Value in Health Dec;23(12):1653-1661. doi: 10.1016/j.jval.2020.08.2095. Epub 2020 Oct 9

PMid: PMID33248521 | PMC number: PMC8262264

Second Cycle Remission Achievement with 7+3 and Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

M Othus;E Estey;G Garcia-Manero;BL Wood;D Stirewalt;J Godwin;J Weick;J Anderson;F Appelbaum;H Erba;R Walter Leukemia Feb;33(2):554-558; Oct 12. doi: 10.1038/s41375-018-0274-y. [Epub ahead of print]

PMid: PMID30315233 | PMC number: PMC6367002

Increasing lengths of first complete remission with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: Analysis of SWOG trial data

M Othus;G Garcia-Manero;JE Godwin;JK Weick;F Appelbaum;H Erba;E Estey Blood (2019) 134 (Supplement_1): 291, abst 613 (American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

E Pogosova-Agadjanyan;A Moseley;F Appelbaum;T Chauncey;I-M Chen;H Erba;J Godwin;I Jenkins;M Fang;M Huynh;K Kopecky;A List;J Naru;J Radich;E Stevens;B Willborg;C Willman;B Wood;Q Zhang;S Meshinchi;D Stirewalt Blood (2019) 134 (Supplement_1): 2691; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Impact of specimen heterogeneity on biomarkers in repository samples from patients with AML: a SWOG report

E Pogosova-Agadjanyan;A Moseley;M Othus;F Appelbaum;T Chauncey;I-M Chen;HP Erba;J Godwin;M Fang;K Kopecky;AF List;G Pogosov;J Radich;C Willman;BL Wood;S Meshinchi;D Stirewalt Biopreservation and Biobanking Feb;16(1):42-52; Nov 27 [Epub ahead of print]

PMid: PMID29172682 | PMC number: PMC5808392

2nd Cycle Remission Achievement with 7+3 is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

M Othus;E Estey;G Garcia-Manero;B Wood;DL Stirewalt;J Godwin;J Weick;J Anderson;F Appelbaum;H Erba;R Walter Blood 132:3978; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

Prognostic methylation markers for survival in cytogenetically normal AML patients treated on SWOG trials

X Qu;M Othus;J Davison;Y Wu;L Yan;E Estey;J Radich;H Erba;F Appelbaum;M Fang Cancer Jul 1;123(13):2472-2481; 2017 Feb 21[Epub ahead of print]

PMid: PMID28222251; PMC5705230

Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival (“Potential Cure”) Over the Past Four Decades: Analysis SWOG Trial Data

M Othus;G Garcia-Manero;JE Godwin;J Weick;JE Anderson;DL Stirewalt;F Appelbaum;HP Erba;EH Estey Blood 2017 130:1301; American Society of Hematology Annual Meeting (December 9-12, 2017, Atlanta, GA), poster

Prediction of CR following a second course of "7+3" in patients with newly diagnosed acute myeloid leukemia not in CR after a first course

M Othus;S Mukherjee;MA Sekeres;JE Godwin;SH Petersdorf;F Appelbaum;H Erba;E Estey Leukemia Aug;30(8):1779-1780; 2016 Feb 29 [Epub ahead of print]

PMid: PMID27055872 | PMC number: PMC4980556

Improved prognostic significance genomic and transcriptional prognostic biomarkers by examining enriched populations of AML blasts: a SWOG report

EL Pogosova-Agadjanyan;A Moseley;BL Wood;F Appelbaum;TR Chauncey;H Erba;J Godwin;M Fang;Kopecky;AF List;M Othus;J Radich;I-M Chen;CL Willman;S Meshinchi;D Stirewalt Blood 128:2890; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster

Prognostic significance of NPM1 mutations in the absence of FLT3-Internal Tandem Duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report

F Ostronoff;M Othus;A Burnett;E Estey;FR Appelbaum;A Evans;J Godwin;A Gilkes;K Kopecky;M Lazenby;AF List;M Fang;V Oehler;S Petersdorf;E Pogosova-Agadjanyan;J Radich;C Willman;S Meshinchi;DL Stirewalt Journal of Clinical Oncology, Apr 1;33(10):1157-1164

PMid: PMID25713434 | PMC number: PMC437285

Cell signalling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia

A Cesano;C Willman;K Kopecky;U Geyko;S Putta;B Louie;M Westfall;N Purvis;D Spellmeyer;C Marimpietri;J Hackett;J Shi;M Walker;X Sun;E Paietta;M Tallman;L Cripe;S Atwater;F Appelbaum;J Radich PLOS ONE 2015 Apr 17;10(4):e0118485. doi: 10.1371/journal.pone.0118485

PMid: PMID25884949 | PMC number: PMCID4401549

Resistance prediction in AML: analysis of 4,601 patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

R Walter;M Othus;AK Burnett;B Lowenberg;H Kantarjian;G Ossenkoppele;R Hills;F Ravandi;A Evans;SA Pierce;F Appelbaum;E Estey Leukemia 29(2):312-320

PMid: PMID25113226 | PMC number: PMC4318722

Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia

B Medeiros;M Othus;M Fang;F Appelbaum;H Erba Haematololgica Mar;100(3):331-335

PMid: PMID25527568 | PMC number: PMC4349271

Prognostic methylation markers for survival in cytogenetically normal AML patients treated on SWOG trials

X Qu;M Othus;J Davison;L Yan;E Estey;J Radich;H Erba;F Appelbaum;M Fang Blood 126(23):688; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral presentation;

Unsuccessful cytogenetic analysis is a poor prognostic feature in acute myeloid leukemia

B Medeiros;M Othus;E Estey;M Fang;F Appelbaum British Journal of Haematology 28(2):245-250;

PMid: PMID24383844 | PMC number: PMC4117470

Declining rates of treatment-related mortality in patients with newly-diagnosed AML given "intense" induction regimens: a report from SWOG and MD Anderson

M Othus;H Kantarjian;S Petersdorf;F Ravandi;J Godwin;J Cortes;S Pierce;H Erba;S Faderl;F Appelbaum;E Estey Leukemia 28(2):289-292;

PMid: PMID23760400 | PMC number: PMC4457325

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia

E Pogosova-Agadjanyan;K Kopecky;S Meshinchi;F Appelbaum;J Anderson;J Godwin;H Lee;A List;V Oehler;S Petersdorf;J Radich;C Willman;D Stirewalt PlosOne 8(8):e70812;

PMid: PMID23967110 | PMC number: PMC3743845

Mutations in the DNMT3A exon 23 independently predict poor outcome in older AML patients: a SWOG report [Letter to the Editor]

F Ostronoff;M Othus;P Ho;DE Geraghty;SH Petersdorf;J Anderson;J Godwin;C Willman;G Radich;F Appelbaum;K Kopecky;DL Stirewalt;S Meshinchi Leukemia 27(1):238-241;

PMid: PMID22722750 | PMC number: PMC4457316

Significance of FAB subclassification of "acute myeloid leukemia, not otherwise specified" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients

RB Walter;M Othus;A Burnett;B Lowenberg;H Kantarjian;GJ Ossenkoppele;RK Hills;K van Montfort;F Ravandi;A Evans;SA Pierce;F Appelbaum;EH Estey Blood 121(13):2424-2431;

PMid: PMID23325837 | PMC number: PMC3612855

A model for prediction of FLT3-ITD and NPM1 (without FLT-3-ITD) positivity in patients with newly diagnosed acute myeloid leukemia [correspondence]

F Ostronoff;M Othus;HM Kantarjian;S Meshinchi;F Ravandi;P Hendrie;S Faderl;P Becker;JE Cortes;JM Pagel;SH Petersdorf;JE Godwin;C Willman;SA Pierce;AF List;RK Sandhu;R Walter;D Stirewalt;FR Appelbaum;EH Estey British Journal of Haematology 163(1):130-132;

PMid: PMID23829510 | PMC number: PMC4128010

Deregulation of stem cell factor (SCF)-AKT-S6 pathway in diagnostic AML samples is associated with disease-free survival: results of a verification study

A Cesano;C Willman;K Kopecky;S Putta;A Cohen;MC Marimpietri;S Atwater;F Appelbaum;G Radich Haematologica 98(suppl.1):abstr. #P956, p.396; European Hematology Association 18th Congress ( June 13-16, 2013, Stockholm, Sweden), poster presentation;

Prediction of CR on reinduction in patients with newly diagnosed acute myeloid leukemia given intensive induction regimens: a report from SWOG and Cleveland Clinic

M Othus;S Mukherjee;MA Sekeres;J Godwin;J Anderson;S Petersdorf;F Appelbaum;HP Erba;E Estey Blood 122:2686; American Society of Hematology meeting (Dec 7-10, 2013, New Orleans, LA), poster presentation;

Prediction of therapeutic resistance in adult acute myeloid leukemia: analysis of 4,550 newly diagnosed patients from MRC/NCRI, HOVON, SWOG, and MD Anderson Cancer Center

R Walter;M Othus;AK Burnett;AK Burnett;B Lowenberg;H Kantarjian;GJ Ossenkoppele;RK Hills;F Ravandi;A Evans;SA Pierce;F Appelbaum;E Estey Blood 122:64; American Society of Hematology annual meeting (Dec 7-10, 2013), oral;

Impact of cytarabine dose in the induction regimen on the outcome of patients with newly diagnosed acute myeloid leukemia with or without NPM1 and/or FLT3 mutations: A SWOG and MD Anderson Cancer Center Report

M Othus;F Ravandi;S Faderl;D Stirewalt;S Pierce;G Borthakur;J Godwin;J Anderson;S Petersdorf;J Cortes;F Ostronoff;E Pogosova-Agadijanyan;F Appelbaum;H Kantarjian;E Estey Blood 122:2686; American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), poster;

Prognostic significance of NPM1 mutations in the absence of FLT3-ITD in older patients with AML: a SWOG report

F Ostronoff;M Othus;S Meshinchi;J Godwin;K Kopecky;A List;V Oehler;S Petersdorf;E Pogosolva-Agadjanyan;J Radich;CL Willman;F Appelbaum;D Stirewalt Blood 122:1315; American Society of Hematology annual meeting (Dec 7-10, New Orleans, LA), poster;

Novel long-term co-culture approach identifies prognostically important heterogeneity of stem/progenitor cell involvement in human acute myeloid leukemia

GS Laszlo;JM Lionberger;BS Harrington;CJ Gudgeon;M Othus;F Appelbaum;ID Bernstein;R Walter Blood 122:1318; ASH annual meeting, poster presentaton

Impact of residual normal metaphases in core binding factor acute myeloid leukemia

B Medeiros;M Othus;M Fang;F Appelbaum;E Estey Cancer 118(9):2420-2423;

PMid: PMID21928314 | PMC number: PMC3490403

Impact of body-mass index in the outcome of adult patients with acute myeloid leukemia

B Medeiros;M Othus;EH Estey;M Fang;F Appelbaum Haematologica 97(9):1401-1404

PMid: PMID22315487 | PMC number: PMCID3436242

A scoring system of prediction of FLT3-ITD positivity in patients with newly diagnosed acute myeloid leukemia: a SWOG, Fred Hutchinson and M.D. Anderson Cancer Center study

F Ostronoff;M Othus;S Meshinchi;F Appelbaum;E Estey Blood 120(21):abst. 2590; American Society of Hematology Annual Meeting, poster;

Declining rates of treatment-related mortality recent in patients with newly-diagnosed AML given "intense" induction regimens: a report from SWOG and MD Anderson

M Othus;H Kantarjian;S Petersdorf;F Ravandi;J Godwin;J Cortes;S Pierce;H Erba;S Faderl;F Appelbaum;E Estey Blood 120(21):abst. 129; American Society of Hematology Annual Meeting, oral;

Single-cell network profiling (SCNP)-based classifier to predict response to induction therapy in elderlly patients with acute myeloid leukemia (AML): validation in two independent sample sets from ECOG and SWOG trials

A Cesano;C Willman;K Kopecky;U Gayko;S Putta;B Louie;M Westfall;N Purvis;D Spellmeyer;C Marimpietri;J Hackett;J Shi;E Paietta;M Tallman;L Cripe;S Atwater;F Appelbaum;J Radich Blood 120(21):abst.2489; American Society of Hematology Annual Meeting, poster;

Prognostic significance of the French-American-British (FAB) morphologic subclassification of "acute myeloid leukemia, not otherwise specified" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients from HOVON, MRC, SWOG, and MD Anderson Cancer Center

R Walter;M Othus;AK Burnett;B Lowenberg;H Kantarjian;G Ossenkoppele;RK Hills;K van Montfort;F Ravandi;S Pierce;F Appelbaum;E Estey Blood 120(21)abst. 540; American Society of Hematology Annual Meeting, oral;

Expression of topoisomerase II isoforms a and B in adult patients with acute myeloid leukemia (AML): relationship to immunophenotype and treatment outcome

A Michelson;K Kopecky;E Koegle;J Anderson;J Godwin;S Petersdorf;A List;C Willman;F Appelbaum;J Radich;M Ganapathi;R Ganapathi;A Advani Journal of Clinical Oncology 29:(suppl; abstr 6564) ASCO 2011 meeting, general poster presentation

Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype [PMID21330329; PMC3069244]

B Xie;M Othus;B Medeiros;M Fang;F Appelbaum;E Estey Haematologica 96(4):631-632

Cytarabine dose for acute myeloid leukemia. (Letter to the Editor) [PMID21631340]

B Medeiros;M Othus;F Appelbaum New England Journal of Medicine 364(11):2167-2168

KIT mutations are very uncommon among elderly AML patients: a SWOG report

F Ostronoff;M Othus;PA Ho;S Petersdorf;JE Anderson;JE Godwin;CL Willman;JP Radich;F Appelbaum;D Stirewalt;S Meshinchi Blood 118(21):abstract 2510; American Society of Hematology (poster presentation);

DNMT3A mutations independently predict poor outcome in older AML patients: a SWOG report

F Ostronoff;M Othus;PA Ho;S Petersdorf;JE Anderson;JE Godwin;C Willman;J Radich;F Appelbaum;D Stirewalt;S Meshinchi Blood 118(210:abstract 3519); American Society of Hematology, poster presentation;

Prognostic import of French-American-British (FAB) system as embedded in 2008 revision of World Health Organization classification of AML

L Newell;M Othus;R Walter;E Petersdorf;T Chauncey;JE Anderson;JE Godwin;K Kopecky;F Appelbaum;E Estey Blood 118(21):abstract 1446; American Society of Hematology, poster presentation;

Prevalence and clinical implications of IDH1 R140 and R172 mutations in older adults with AML: a report from SWOG

PA Ho;M Othus;K Kopecky;F Ostronoff;S Petersdorf;JE Anderson;JE Godwin;CL Willman;JP Radich;F Appelbaum;D Stirewalt;S Meshinchi Blood 118(21):abstract 3516; American Society of Hematology, poster presenation;

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a Children's Oncology Group and Southwest Oncology Group Study [PMID21873548; PMC3208275]

P Ho;K Kopecky;T Alonzo;R Gerbing;K Miller;J Kuhn;R Ries;S Raimondi;B Hirsch;V Oehler;C Hurwitz;J Franklin;A Gamis;S Petersdorf;J Anderson;J Godwin;G Reaman;C Willman;I Bernstein;J Radich;F Appelbaum;D Stirewalt Blood 118(17):4561-4566

Prediction of early death following induction therapy for newly diagnosed acute leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

R Walter;M Othus;G Borthakur;F Ravandi;J Cortes;S Pierce;F Appelbaum;H Kantarjian;E Estey Journal of Clinical Oncology, 29(33):4417-23;

PMid: PMID21969499 | PMC number: PMC3221524

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study[PMID20376086; PMC2944692]

PA Ho;TA Alonzo;KJ Kopecky;KL Miller;J Kuhn;R Gerbing;S Raimondi;B Hirsch;V Oehler;C Hurwitz;J Franklin;A Gamis;S Petersdorf;J Anderson;GH Reaman;LH Baker;C Willman;I Bernstein;G Radich;F Appelbaum;D Stirewalt;S Meshinchi Leukemia 24(5):909-913;

The effect of complete remission (CR) and CR with incomplete platelet recovery (CRp) on outcome in acute myeloid leukemia: a combined eastern cooperative oncology group (ECOG), Southwest Oncology Group (SWOG), and M.D. Anderson Cancer Center study

Journal of Clinical Oncology 28(10):1766-1771;

Prognostic impact of monosomal karyotype in young adults and elderly acute myeloid leukemia: the Southwest Oncology Group experience [PMID: 20562328; NIHMSID244631]

BC Medeiros;M Othus;M Fang;D Roulston;FR Appelbaum Blood 116(13):2224-2228

PMid: PMID20562328 | PMC number: PMC3709629

Over-expression of novel IRF8 splice variants is associated with a significant decrease in relapse-free survival in adult AML patients

E Porosova-Agadjanyan;K Kopecky;H Lee;J Anderson;J Godwin;A List;S Meshinchi;V Oehler;S Petersdorf;C Willman;F Appelbaum;JP Radich;D Stirewalt Blood 116:Abstract 1679; American Society of Hematology Annual Meeting; poster

Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a Children's Oncology Group and Southwest Oncology Group Study

P. Ho;K. Kopecky;T. Alonzo;R. Gerbing;K. Miller;J. Kuhn;R. Ries;S. Raimondi;B. Hirsch;V. Oehler;C Hurwitz;J. Franklin;A. Gamis;S. Petersdorf;J. Anderson;J. Godwin;G. Reaman;C. Willman;I. Bernstein;J. Radich;F. Appelbaum;D. Stirewalt;S. Meshinchi Blood 2010 116:Abstract 2737; American Society of Hematology Annual Meeting; poster

Influence of residual normal metaphases in patients with monosomal karyotype

B Xie;M Othus;B Medeiros;M Fang;F Appelbaum;E Estey Blood 116:Abstract 1671; ASH 2010 meeting; poster presentation

Very late antigen-4 (VLA-4) function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia [PMC2630271; PMID18927435]

PS Becker;KJ Kopecky;AN Wilks;JM Harlan;CL Willman;SH Petersdorf;T Papayannopoulou;FR Appelbaum Blood 113(4):866-874

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML? [PMID18342809]

CL Willman Best Practice & Research Clinical Hematology 21(1)21-28

Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials [PMID17197435]

N Kuptsova;KJ Kopecky;J Godwin;J Anderson;A Hoque;CL Willman;ML Slovak;CB Ambrosone Blood 109(9):3936-3944

Age and acute myeloid leukemia

FR Appelbaum;H Gundacker;DR Head;ML Slovak;CL Willman;JE Godwin;JE Anderson;SH Petersdorf Blood 107(9):3481-3485

Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.

CS Wilson;GS Davidson;SB Martin;E Andries;J Potter;R Harvey;K Ar;Y Xu;KJ Kopecky;DP Ankerst;H Gundacker;ML Slovak;M Mosquera-Caro;IM Chen;DL Stirewalt;M Murphy;FA Schultz;H Kang;X Wang;JP Radich;FR Appelbaum;SR Atlas;J Godwin;CL Willman Blood 108(2):685-696

The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.

FR Appelbaum;KJ Kopecky;MS Tallman;ML Slovak;HM Gundacker;HT Kim;GW Dewald;HM Kantarjian;SR Pierce;EH Estey British Journal of Haematology 135:165-173

Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials.

JR Weiss;KJ Kopecky;J Godwin;J Anderson;CL Willman;KB Moysich;ML Slovak;A Hoque;CB Ambrosone Leukemia 20:2169-2171

PMid: PMID17008887

Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukemia

DL Stirewalt;S Meshinchi;SJ Kussick;KM Sheets;E Pogosova-Agadjanyan;CL Willman;JP Radich British Journal of Haematology 124:481-484

Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group Clinical Trial

CL Bennett;D Hynes;J Godwin;TJ Stinson;RM Golub;FR Appelbaum Cancer Investigation 19(6):603-610

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia

DL Stirewalt;KJ Kopecky;S Meshinchi;FR Appelbaum;ML Slovak;CL Willman;JP Radich Blood 97(11):3589-3595

The significance of trisomy 8 in myeloid leukemia: a Southwest Oncology Group (SWOG) study.

ML Slovak;H Gundacker;SR Wolman;FR Appelbaum American Journal of Human Genetics 69(4):232(#285)

Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sevsitive and specific.

DL Stirewalt;CL Willman;JP Radich Leukemia Research 25:1085-1088

Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia

FF Zhang;JL Murata-Collins;P Gaytan;SJ Forman;KJ Kopecky;CL Willman;FR Appelbaum;ML Slovak Genes Chromosomes & Cancer 28:318-328

Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia

C Crump;C Chen;FR Appel baum;KJ Kopecky;SM Schwartz;CL Willman;ML Slovak;NS Weiss Cancer Epidemiology Biomarkers & Prevention 9:457-460

Acute myelogenous leukemia and aging. Clinical interactions.

JE Lancet;CL Willman;JM Bennett Hematology/Oncology Clinics of North America 14(1):251-267

Microsatellite Instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature

LM Rimsza;KJ Kopecky;J Ruschulte;I-M Chen;ML Slovak;C Karanes;J Godwin;A List;CL Willman Leukemia 14:1044-1051

24-color karyotyping (multiplex or M-fish) reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia

ML Slovak;F Zhang;JL Murata-Collins;KJ Kopecky;CL Willman;SJ Forman;FR Appelbaum Blood 94(10)Suppl.1:657a(#2918)part_1_of_2

A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031).

JE Godwin;KJ Kopecky;DR Head;CL Willman;CP Leith;HE Hynes;SP Balcerzak;FR Appelbaum Blood 91(10):3607-3615

AML in the elderly: a biologically distinct disease in which MDR1 expression and unfavorable cytogenetics contribute to poor clinical response. Studies of the Southwest Oncology Group.

CP Leith;KJ Kopecky;I Chen;T McConnell;ML Slovak;DR Head;J Godwin;FR Appelbaum;CL Willman Hematology and Blood Transfusion 39 Acute Leukemias VII:413-421

Biological features of acute myeloid leukemia in the elderly.

CP Leith;KJ Kopecky;CL Willman Blood 92(2):697-699

Economic analysis of granulocyte colony stimulating factor (G-CSF) as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group (SWOG) clinical trial.

CL Bennett;D Hynes;J Godwin;TJ Stinson;RM Golub;FR Appelbaum Blood 92(10)(Suppl.1):615a(#2538)

Cell cycle arrest and therapeutic sensitivity in de novo AML.

D Banker;C Willman;M Groudine;F Appelbaum Blood 90(10)Suppl.1:67a(#290)

Development of a highly sensitive multiparameter flow cytometric assay correlating MDR1 expression and function: Clinical application to acute myeloid leukemia.

CP Leith;KJ Kopecky;I Chen;FR Appelbaum;DR Head;JE Godwin;CL Willman Drug Resistance in Leukemia and Lymphoma II 3-Ch.37:307-314

Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.

CP Leith;KJ Kopecky;J Godwin;T McConnell;ML Slovak;I Chen;DR Head;FR Appelbaum;CL Willman Blood 89(9):3323-3329

Frequency and clinical significance of expression of the multidrug resistance proteins, MDR1, MRP1 and LRP in acute myeloid leukemia patients less than 65 years old. A Southwest Oncology Group study.

CP Leith;KJ Kopecky;I-M Chen;M Slovak;DR Head;J Weick;FR Appelbaum;CL Willman Blood 90(10)Suppl.1:389a(#1733)

Trisomy 10 as the sole cytogenetic abnormality in hematologic neoplasia.

K Theil;SM Dobin;T McConnell;ML Slovak;S Kahwash;M Brownell;A Chaudhury Blood 90(10):223b(#3742)

AML in the elderly: Stratification by MDR1 phenotype, secondary vs de novo status, and cytogenetics identifies patients with high complete remission (CR) rates. A Southwest Oncology Group study.

CP Leith;KJ Kopecky;J Godwin;T McConnell;M Slovak;IM Chen;DR Head;F Appelbaum;CL Willman American Society of Clinical Oncology 15:359(#1058)

Cytogenetics, MDR1, and disease status in elderly AML identify a subgroup with a high complete remission (CR) rate: A Southwest Oncology Group study.

ML Slovak;KJ Kopecky;T McConnell;CP Leith;J Godwin;IM Chen;C Rankin;DR Head;F Appelbaum;CL Willman British Journal of Haematology 93(Suppl.2):134(#522)

Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations.

WT Beck;TM Grogan;CL Willman;C Cordon-Cardo;DM Parham;JF Kuttesch;M Andreff;SE Bates;CW Berard;JM Boyett;NA Brophy;HJ Broxterman;HSL Chan;WS Dalton;M Dietel;AT Fojo;RD Gascoyne;D Head;PJ Houghton;DK Srivastava;M Lehnert;CP Leith;E Paietta;ZP Pavelic;L Rimsza;IB Roninson;BI Sikic;PR Twentyman;R Warnke;R Weinstein Cancer Research 56:3010-3020

Acute myeloid leukemia in the elderly: high frequency of trilineage dyspoiesis suggests that elderly AML is biologically similar to AML arising secondary to myelodysplasia.

CP Leith;KJ Kopecky;CL Willman;M Slovak;T McConnell;J Godwin;I Chen;FR Appelbaum;DR Head Blood 88(10)Suppl:559a(#2225)

Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1).

CL Willman Leukemia 10(Suppl.1):S33-S35

A subgroup of elderly AML patients with a high complete remission rate can be defined.

ML Slovak;KJ Kopecky;T McConnell;CP Leith;J Godwin;IM Chen;C Rankin;DR Head;F Appelbaum;CL Willman Trends in Onco-Hematology 4(2):34-35

Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux- cases

CP Leith;IM Chen;KJ Kopecky;FR Appelbaum;DR Head;JE Godwin;JK Weick;CL Willman Blood 86(6):2329-2342

Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine wiht our without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group Study.

J Godwin Journal of the National Cancer Institute Monography 19:31-35

Genetic heterogeneity of acute myeloid leukemia (AML) with FAB-AML M3 morphology

DR Head;F Behm;S Raimondi;A Carroll;M Slovak;E Magenis;C Willman;J Licht;A Scott;MV Gresik;J Downing;D Butler;T Motroni International Academy of Pathology Book of Abstracts :112A(#651)

Heterogeneity in CBFB/MYH11 fusion messages encoded by inv(16) and t(16;16) in acute myelogenous leukemia (AML)

J Downing;S Shurtleff;S Meyers;S Hiebert;S Raimondi;D Head;C Willman;S Wolman;A Carroll;F Behm;F Collins;P Liu International Academy of Pathology Book of Abstracts :109A(#630)

Amplification of the E2F-1 transcription factor gene in the HEL erythroleukemia cell line

M Saito;K Helin;MB Valentine;BB Griffith;CL Willman;E Harlow;AT Look Genomics 25:130-138

Heterogeneity in CBF'/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia

SA Shurtleff;S Meyers;SW Hiebert;SC Raimondi;D Head;CL Willman;SR Wolman;ML Slovak;AJ Carroll;F Behm;MG Hulshof;TA Motroni;T Okuda;P Liu;FS Collins;JR Downing Blood 85(12):3695-3703

Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia.

B Mehrotra;TI George;K Kavanau;H Avet-Loiseau;D Moore II;Cl Willman;ML Slovak;S Atwater;DR Head;MG Pallavicini Blood 86(3):1139-1147

Trisomy 11: an association with stem/progenitor cell immunophenotype.

ML Slovak;ST Traweek;CL Willman;DR Head;KJ Kopecky;RE Magenis;FR Appelbaum;SJ Forman British Journal of Hematology 90:266-273

MDR1 expression is highly predictive for achievement of complete remission (CR) in acute myeloid leukemia (AML) in the elderly: A Southwest Oncology Group study.

CP Leith;KJ Kopecky;IM Chen;JE Godwin;FR Appelbaum;DR Head;CL Willman Blood 86(10)(Suppl.1)(#1061):269a

CD56: A determinant of extramedullary and central nervous system (CNS) involvement in acute myeloid leukemia (AML). Modern Pathology 7(1):120A (#695)

AA Scott;KJ Kopecky;TM Grogan;DR Head;FA Troy, II;J Mullen;J Ya;FR Appelbaum;KS Theil;CL Willman Intl Academy of Pathology 120A(#695)/Lab Investigation 70(1):120A(#695)

HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3

AA Scott;DR Head;KJ Kopecky;FR Appelbaum;KS Theil;MR Grever;I-M Chen;MH Whittaker;BB Griffith;JD Licht;S Waxman;MM Whalen;AD Bankhurst;LC Richter;TM Grogan;CL Willman Blood 84(1):244-255

Trisomy 8: A primary cytogenetic anomaly in leukemia?

SR Wolman;ML Slovak;CL Willman;FR Appelbaum;RE Magenis Blood 84(10)(Suppl.1):308a(#1219)

Comparative genomic hybridization (CGH) and cytogenetics provide complementary information to identify genetic abnormalities in AML.

H Avet-Loiseau;K Thiel;T McConnell;CL Willman;S Atwater;MG Pallavicini Blood 84(10)(Suppl.1)(#2380):599a

Correlation of functional efflux and multidrug resistance (MDR1) expression in acute myeloid leukemia (AML) in the elderly: MDR1 and secondary AML status are independent predictors of complete remission (CR).

CP Leith;KJ Kopecky;I-M Chen;JE Godwin;FR Appelbaum;DR Head;CL Willman Blood 84(10)(Suppl.1)(#1493):377a

Acute promyelocytic leukemia associated wit t(11;17) is a discrete syndrome that fails to respond to retinoic acid.

JD Licht;C Chomienne;A Goy;A Chen;AA Scott;DR Head;JL Michaux;Y Wu;A DeBlasio;WH Miller Jr;AD Zelenetz;CL Willman;Z Chen;A Zelent;E Macintyre;A Veil;J Cortes;H Kantarjian;S Waxman Blood 84(10)(Suppl.1)(#1500):379a

An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the t(8;21) (q22;q22).

JR Downing;DR Head;AM Curcio-Brint;MG Hulshof;TA Motroni;SC Raimondi;AJ Carroll;HA Drabkin;CL Willman;KS Theil;CI Civin;P Erikson Blood 81(11):2860-2865

HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities.

SP Hunger;DC Tkachuk;MD Amylon;MP Link;AJ Carroll;Jl Welborn;CL Willman;ML Cleary Blood 81(12):3197-3203

Identification and characterization of a previously unrecognized form of acute leukemia co-expressing myeloid and natural killer (NK) cell-associated antigens (CD56).

AA Scott;DR Head;K Theil;LM Chen;MH Whittaker;CL Willman International Academy of Pathology 68:100A(#575)

Clinical significance and functional analysis of the expression of the multidrug resistance gene (MDR1) in acute myeloid leukemia (AML).

CP Leith;LM Chen;BB Griffith;DR Head;AF List;FR Appelbaum;CL Willman International Academy of Pathology 68:94A(#544)

Functional assessment of the multidrug (MDR1) resistance efflux pump in acute myeloid leukemia (AML): Identification of CD34-, CD33+, MRK16+ (MDR1+) cases lacking functional dye efflux.

CP Leith;KJ Kopecky;IM Chen;BB Griffith;FR Appelbaum;CL Willman Blood 82(10)(Suppl.1):(#1754)